163 related articles for article (PubMed ID: 7734404)
1. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes.
Hirosumi J; Nakayama O; Fagan T; Sawada K; Chida N; Inami M; Takahashi S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):357-63. PubMed ID: 7734404
[TBL] [Abstract][Full Text] [Related]
2. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates.
Hirosumi J; Nakayama O; Chida N; Inami M; Fagan T; Sawada K; Shigematsu S; Kojo H; Notsu Y; Okuhara M
J Steroid Biochem Mol Biol; 1995 Apr; 52(4):365-73. PubMed ID: 7734405
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new non-steroidal 5 alpha-reductase inhibitor, FK143, on the prostate gland in beagle dogs.
Inami M; Kawamura I; Naoe Y; Tsujimoto S; Mizota T; Manda T; Shimomura K
Jpn J Pharmacol; 1997 Jun; 74(2):187-94. PubMed ID: 9243327
[TBL] [Abstract][Full Text] [Related]
4. 4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II).
Sawada K; Okada S; Golden P; Kayakiri N; Sawada Y; Hashimoto M; Tanaka H
Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):481-91. PubMed ID: 10319427
[TBL] [Abstract][Full Text] [Related]
5. Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes.
Kojo H; Nakayama O; Hirosumi J; Chida N; Notsu Y; Okuhara M
Mol Pharmacol; 1995 Sep; 48(3):401-6. PubMed ID: 7565619
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
J Pharmacol Exp Ther; 1998 Mar; 284(3):914-20. PubMed ID: 9495849
[TBL] [Abstract][Full Text] [Related]
8. Species differences in prostatic steroid 5 alpha-reductases of rat, dog, and human.
Liang T; Cascieri MA; Cheung AH; Reynolds GF; Rasmusson GH
Endocrinology; 1985 Aug; 117(2):571-9. PubMed ID: 4017948
[TBL] [Abstract][Full Text] [Related]
9. FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates.
Nakayama O; Hirosumi J; Chida N; Takahashi S; Sawada K; Kojo H; Notsu Y
Prostate; 1997 Jun; 31(4):241-9. PubMed ID: 9180934
[TBL] [Abstract][Full Text] [Related]
10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
12. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
Hirsch KS; Jones CD; Audia JE; Andersson S; McQuaid L; Stamm NB; Neubauer BL; Pennington P; Toomey RE; Russell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5277-81. PubMed ID: 8389478
[TBL] [Abstract][Full Text] [Related]
13. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats.
Maruyama S; Nagasue N; Dhar DK; Yamanoi A; El-Assal ON; Satoh K; Okita K
Clin Cancer Res; 2001 Jul; 7(7):2096-104. PubMed ID: 11448929
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers.
Katashima M; Irino T; Shimojo F; Kawamura A; Kageyama H; Higashi N; Miyao Y; Tokuma Y; Hata T; Yamamoto K; Sawada Y; Iga T
Clin Pharmacol Ther; 1998 Mar; 63(3):354-66. PubMed ID: 9542479
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
16. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
17. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
19. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
20. Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
Kaefer M; Audia JE; Bruchovsky N; Goode RL; Hsiao KC; Leibovitch IY; Krushinski JH; Lee C; Steidle CP; Sutkowski DM; Neubauer BL
J Steroid Biochem Mol Biol; 1996 May; 58(2):195-205. PubMed ID: 8809201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
